PharmFree Scorecard

Conflict of Interest Policies at Academic Medical Centers

Most of the 150 U.S. medical schools are failing when it comes to building strong conflict of interest policies to limit pharmaceutical marketing on campus, according to the American Medical Student Association (AMSA) PharmFree Scorecard released today. Only seven institutions received 'A's for their conflict of interest policies.

“The schools that earned ‘A' and ‘B' scores are to be commended for setting a high bar and aggressively moving forward to ensure medical education, training and patient care is free of commercial bias,” says RxP executive director Robert Restuccia. “While we still have a long way to go, we are optimistic that the growing momentum for reform will change the landscape and there will be great improvement next year.”

To check out the Scorecard, go to www.amsascorecard.org.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.